MGD-Associated Dry Eye Disease: Pathophysiology, Current and Emerging Therapies for Improved Outcomes

Complimentary

Released on 9/5/24
Expires on 9/5/25

Start Activity

Program Description

This webcast provides an update on the MGD-DED. Eyelid inflammation, microbial growth, associated skin disorders, and potentially severe corneal complications make MGD a complex multifactorial disorder. MGD is a heterogeneous condition arising from any combination of five separate pathophysiological mechanisms: eyelid inflammation, conjunctival inflammation, corneal damage, microbiological changes, and DED resulting from tear film instability.

Intended Audience

Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with meibomian gland dysfunction (MGD) associated dry eye disease (DED).

Commercial Supporter

This activity is supported by an educational grant from Alcon Vision, LLC.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

  • Summarize the pathophysiology and diagnosis of MGD-associated DED
  • Assess real-world evidence surrounding current treatments for MGD-associated DED
  • Interpret key clinical trial data of emerging agents for the potential treatment of MGD-associated DED

Accredited Providers

This activity is provided by the University of Cincinnati and MedNet.

      

Physicians (ACCME) Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MedNet. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The University of Cincinnati designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Credit Information

Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors, and allows reciprocity for AANPCP continuing education credit. Maximum of 1.5 hours.

Note to Physician Assistants
AAPA accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME. Maximum of 1.5 hours.

Planner and Speaker Disclosure Policy

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Faculty

Walter Whitley, OD, MBA
Virginia Eye Consultants
Norfolk, VA

Dr. Whitley discloses the following:
Advisory Board Member: Alcon, Allergan, Bausch and Lomb, Bruder Healthcare, Science Based Health, Sun Pharmaceuticals, Tarsus Pharmaceuticals, Visus Pharmaceuticals
Consultant: Alcon, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, CSI Dry Eye Inc., Epion, Glaukos, Harrow, 12-Vision, Inc., Iveric Bio, Mediprint Pharma, Nordic Pharma, OD Immersion, Regener-Eyes, Sight Sciences, Thea Pharmaceuticals, Trukera, Viatris
Speaker: Alcon, Allergan, Apellis Pharmaceuticals, Bausch and Lomb. Co-Chief Medical Editor for: Modern Optometry. Contributing Editor for: Review of Optometry. Co-Medical Editor for: Dry Eye Coach

Eric D. Donnefeld, MD
Clinical Professor of Ophthalmology
New York University Langone Medical Center
Ophthalmic Consultants of Long Island
New York, NY

Dr. Donnenfeld discloses the following:
Consultant: Acufocus, Aeon, Aldeyra, Allegro, Allergan, Alcon, Aurion, Avedro, Avellino Labs, Bausch & Lomb, BVI, Blephex, CorneaGen, Covalent, CRST, Crystilex, Dompe, ELT Sight, EyePoint Pharma, Foresight, Glaukos, Horizon Surgical Systems, Icon Biosciences, Ivantis, Iveric Bio, Johnson & Johnson, Kala, Katena, Lacripen, Layerbio, Lensgen, Mati Pharmaceuticals, Melt Pharmaceuticals, MDBackline, Merck, Mynosis, Nanowafer, Nordic Pharma, Novabay, Novaliq, Novartis, Ocular Innovations, Ocular Therapeutics, Oculis, Omega Ophthalmics, Omeros, Oyster Point, Pogotec, PRN, Rayner, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Surface, SUN, Tarsus, Tearscience, Thea, Trukera, Versant Ventures, Visionary Ventures, Visus, Zeiss

Instructions

In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

ACCME – Amedco
Phone Number: 651-789-3730
E-Mail: Sheryl@AmedcoEmail.com

Privacy Policy

myCME privacy policy

Webcast

Time to Complete: 90 minutes

Released: September 5, 2024

Expires: September 5, 2025

Maximum Credits:
1.50 / AMA PRA Category 1 CreditsTM